Search | Clinical Trials Finder

Conditions: Infections, Papillomavirus, Papillomavirus Vaccines
Interventions: CervarixTM, HPV investigational vaccine GSK568893A, different formulations; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Denver, Colorado • Golden, Colorado • Salt Lake City, Utah

Conditions: Human Papillomavirus-Related Carcinoma
Interventions: Biospecimen Collection, HPV16 RG1 VLP Vaccine, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cervical Cancer, Hpv, Warts
Interventions: Quadrivalent HPV for types 6, 11, 16 and 18; Biological
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 9 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Infections, Papillomavirus
Interventions: Gynaecological follow-up; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 18
States / cities: Clearwater, Florida • Miami, Florida • Honolulu, Hawaii + 14 more

Conditions: Recurrent Respiratory Papillomatosis
Interventions: Human Papillomavirus Vaccine; Biological
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Human Papilloma Virus Vaccine
Interventions: STOP-HPV-Online, STOP-HPV-LC; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 9 Years to 17 Years
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Human Papillomavirus Infections
Interventions: Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more

Conditions: Vaccine Hesitancy
Interventions: INVEST; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Durham, North Carolina • Columbia, South Carolina

Conditions: Completion of Three Dose Series of HPV, Improvement in Vaccine Intervals Between HPV Doses
Interventions: Telephone reminder, Text Message reminder; Other
Lead sponsor: University of Rochester; Other
Eligibility: 10 Years to 21 Years
Enrollment: 749 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Rochester, New York

Conditions: Human Papillomavirus-Related Carcinoma
Interventions: Best Practice, Educational Intervention, Health Promotion and Education, Internet-Based Intervention; Other
Lead sponsor: Emory University; Other
Eligibility: 9 Years and older
Enrollment: 1,836 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infection, Precancerous Condition
Interventions: Gardasil; Biological
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more

Conditions: Human Papillomavirus
Interventions: Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®; Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Infections, Papillomavirus, Papillomavirus Vaccines
Interventions: Cervarix, Placebo control; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 26 Years and older · Female only
Enrollment: 5,752 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 36
States / cities: Fountain Valley, California • Aurora, Colorado • Golden, Colorado + 29 more

Conditions: Human Papillomavirus
Interventions: Baseline Survey, Current CDC Message, Cervical Cancer Message, Control Message, Post-Intervention Survey; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 1,320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HPV-Associated Cancers
Interventions: Ad-E6E7, MG1-E6E7, Atezolizumab; Biological
Lead sponsor: Turnstone Biologics, Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Miami, Florida • Billings, Montana • New York, New York + 2 more

Conditions: Human Papillomavirus Vaccination
Interventions: Text message reminder; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 14 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Papilloma Virus
Interventions: Usual Care, ECA-HPV App with Clinic Notification and Adolescent Functions Disabled, ECA-HPV App with Clinic Notification Function Enabled, ECA-HPV App with Adolescent Function Enabled, ECA-HPV App with Clinic Notification and Adolescent Functions Enabled; Behavioral
Lead sponsor: Tufts Medical Center; Other
Eligibility: 8 Years to 12 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions: Gardasil, Survey; Biological · Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 26 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Uterine Cervical Cancer
Interventions: Not listed
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 26 Years · Female only
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Athens, Ohio • Gallipolis, Ohio • Logan, Ohio + 1 more

Conditions: Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions: BNT113, Pembrolizumab; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more

Conditions: Infections, Papillomavirus, Papillomavirus Vaccines
Interventions: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 40
States / cities: Chandler, Arizona • San Diego, California • San Francisco, California + 36 more

Conditions: Adult Solid Tumor
Interventions: SQZ-eAPC-HPV, Pembrolizumab; Biological
Lead sponsor: SQZ Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Scottsdale, Arizona • Duarte, California • Aurora, Colorado + 5 more

Conditions: Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
Interventions: Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group; Behavioral
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Vaccination
Interventions: Informational Animation Video, Personal Narrative Video; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: Not listed
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis

The STOP-HPV Scale Up Study

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Increasing Vaccine Uptake Among Adolescents in the Rural South

The Efficacy of Reminders to Complete HPV Series

A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

A Phase I Clinical Trial of an HPV Therapeutic Vaccine

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Tailoring of Vaccine-Focused Messages: Disease Salience

This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers

SMS HPV Vaccine Reminders

Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

Community Awareness, Resources and Education (CARE II): Project 3

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Culturally Tailored HPV Psychoeducational Multimedia Intervention

"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake